Fundraising Fox
Precision Neuroscience
Unicorn · $1BNew York, US · Founded 2020 · Delaware corporation · 13 known investors
Find your way into Precision Neuroscience
Sign up to see every warm intro you have to Precision Neuroscience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Precision Neuroscience team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Precision Neuroscience develops a minimally invasive, high-bandwidth brain-computer interface, including its Layer 7 cortical interface, initially aimed at helping people with paralysis control digital devices and robotics using their thoughts. The company works with hospital clinical partners on implanted studies and positions its technology as removable and upgradable without damaging the brain.
Founders & leadership
Precision Neuroscience was founded in 2020 by Benjamin Rapoport and Michael Mager.
Board
Investors · 13
How we know: Alumni Ventures's portfolio page · Not right? Tell us
.jpeg){kind=logo}
How we know: B Capital Group's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: Basecamp Fund's portfolio page · Not right? Tell us
How we know: Draper Associates's portfolio page · Not right? Tell us
How we know: Forepont Capital Partners's portfolio page · funding news · the VCSheet dataset · Not right? Tell us
How we know: Perridon Ventures's portfolio page · Not right? Tell us
How we know: SCI Ventures's portfolio page · press coverage · funding news · Not right? Tell us
How we know: Steadview Capital's portfolio page · offering press articles · funding news · press coverage · Not right? Tell us
Also in the syndicate · 3
Reported raises · per SEC filings
Form D private placements$422.3M disclosed across 5 of 6 rounds · 2021–2026
▶$250MraisedSep 2026 · 46 investors · Other Health CareRule 506(b)
- Michael MagerExecutive Officer, Director
- Konstantinos AlatarisExecutive Officer, Director
- Craig MermelExecutive Officer, Director
- Benjamin RapoportExecutive Officer, Director
- Ravi MehtaDirector
- Howard MorganDirector
- Michael KaswanExecutive Officer
- Michael GollerDirector
- Stephen BiggarDirector
- Amount sold
- $250M
- First sale
- Sep 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$93.1MraisedOct 2024 · 21 investors · Other Health CareRule 506(b)
- Eric M. AttiasDirector
- Craig MermelDirector, Executive Officer
- Howard MorganDirector
- MIchael KaswanExecutive Officer
- Benjamin RapoportDirector, Executive Officer
- Ravi MehtaDirector
- Jason ChenDirector
- Michael MagerDirector, Executive Officer
- Offering amount
- $150M
- Amount sold
- $93.1M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$27.5MraisedApr 2024 · 5 investors · Other Health CareRule 506(b)
- Mike KaswanExecutive Officer
- Benjamin RapoportDirector, Executive Officer
- Michael MagerDirector, Executive Officer
- Jason ChenDirector
- Craig MermelDirector, Executive Officer
- Howard MorganDirector
- Eric M. AttiasDirector
- Ravi MehtaDirector
- Offering amount
- $45M
- Amount sold
- $27.5M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$41.2MraisedFeb 2023 · 20 investors · Other Health CareRule 506(b)
- Benjamin RapoportExecutive Officer, Director
- Ravi MehtaDirector
- Eric M. AttiasDirector
- Jason ChenDirector
- Howard MorganDirector
- Craig MermelExecutive Officer, Director
- Michael MagerExecutive Officer, Director
- Offering amount
- $42M
- Amount sold
- $41.2M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$10.5MraisedApr 2021 · 2 investors · Other Health CareRule 506(b)
- Benjamin RapoportExecutive Officer, Director
- Craig MermelDirector
- Michael MagerExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $10.5M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Legal entities · 1
corporate structureIn the news
Frequently asked questions
- What does Precision Neuroscience do?
- Precision Neuroscience develops a minimally invasive, high-bandwidth brain-computer interface, including its Layer 7 cortical interface, initially aimed at helping people with paralysis control digital devices and robotics using their thoughts. The company works with hospital clinical partners on implanted studies and positions its technology as removable and upgradable without damaging the brain.
- Who founded Precision Neuroscience?
- Precision Neuroscience was founded by Benjamin Rapoport, Michael Mager in 2020.
- Who are Precision Neuroscience's investors?
- Precision Neuroscience's investors include Alumni Ventures, B Capital Group, B4 Capital, Basecamp Fund, Draper Associates, Forepont Capital Partners, Perridon Ventures, SCI Ventures and 2 more.
- How much funding has Precision Neuroscience raised?
- Precision Neuroscience has disclosed $422.3M raised across 5 of its 6 known rounds.
- Where is Precision Neuroscience headquartered?
- Precision Neuroscience is headquartered in New York, US.